OnKure Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from OnKure Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-399.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-94.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+56%Cash, after subtracting all debt, equals 56% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
OnKure Therapeutics, Inc. made a loss over the last year. OnKure Therapeutics, Inc. owes $0.04 for every $1 it owns. OnKure Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOnKure Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.61The share price is 0.61 times OnKure Therapeutics, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$104 MThe total market value of all of OnKure Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$172 MWhat OnKure Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.25Net worth divided by the number of shares. The share price of $2.58 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-46.9%OnKure Therapeutics, Inc. lost 46.9% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
Owes vs Owns
0.04×OnKure Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneOnKure Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossOnKure Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredOnKure Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOnKure Therapeutics, Inc. held $59 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For OnKure Therapeutics, Inc.: $104 M ÷ $172 M (30 Jun 2026) = 0.6.
What is OnKure Therapeutics, Inc.'s return on equity?
OnKure Therapeutics, Inc. lost 46.9% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
How much does OnKure Therapeutics, Inc. owe compared with what it owns?
OnKure Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does OnKure Therapeutics, Inc. pay a dividend?
No. OnKure Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.